GlassScriptPhysician profile
Lisa M West
NPI 1346220290
$20,245.21
in general payments reported to CMS, 2019-2025
34 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 86% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,934 · 2020: $708 · 2021: $3,672 · 2022: $3,303 · 2023: $1,899 · 2024: $1,474 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,438 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,437.95 |
| Education | $121.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $7,322.21 | 2019 | |
| Allergan, INC. | $4,890.85 | 2019-2023 | |
| Abbvie INC. | $2,910.40 | 2019-2025 | |
| Novo Nordisk INC | $806.46 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $669.62 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $414.70 | 2023-2025 | |
| Lilly USA, LLC | $408.69 | 2022-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.20 | 2019-2024 | Xifaxan |
| Intuitive Surgical, INC. | $271.86 | 2019 | |
| Myovant Sciences INC. | $239.64 | 2021-2022 | |
| Exeltis, USA INC. | $234.21 | 2020-2025 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $167.34 | 2022 | |
| Therapeuticsmd, INC. | $164.61 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $162.44 | 2021 | |
| Mayne Pharma Commercial LLC | $140.43 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $122.45 | 2020-2024 | Tymlos |
| Amgen INC. | $112.26 | 2020-2025 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $111.86 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $101.25 | 2021-2024 | |
| Millicent US INC | $76.12 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $75.15 | 2020-2023 | Balcoltra |
| Scynexis, INC. | $70.14 | 2022 | |
| Conmed Corporation | $66.67 | 2019 | |
| Ardelyx, INC. | $64.42 | 2024-2025 | Ibsrela |
| Lupin INC. | $46.25 | 2019-2021 | |
| Mycovia Pharmaceuticals, INC. | $45.02 | 2022-2023 | Vivjoa |
| Evofem Biosciences, INC. | $43.93 | 2020-2021 | |
| Kvk-Tech, INC. | $42.69 | 2020 | |
| Merck Sharp & Dohme LLC | $41.04 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.74 | 2019-2021 | |
| Duchesnay USA Incorporated | $20.00 | 2019 | |
| Coopersurgical, INC. | $17.22 | 2022 | |
| Currax Pharmaceuticals LLC | $13.99 | 2021 | |
| Agile Therapeutics, INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.